Member since: 2016
Organization: Shoukat Khanum memorial hospital
Great results, I like it very much.
Application Area: Prognostic marker for triple negative breast cancer and other tumors
"Staining of PD-l1 is excellent and easy to use on the Benchmark Ultra."
Member since: 2019
Organization: Halton Healthcare
Reliable results with better patient outcomes!
Application Area:Clinical laboratory
"Using a small breast biopsy specimen, it is possible to clearly determine if atezolizumab is the best treatment."
VENTANA PD-L1 (SP142) Assay is intended for the immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a BenchMark IHC/ISH instrument.
Determination of PD-L1 status is indication-specific and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.
VENTANA PD-L1 (SP142) Assay is indicated as an aid for identifying patients for treatment with the therapies listed in Table 1 for the respective indications and cutoffs in accordance with the approved therapeutic product labeling.
VENTANA PD-L1 (SP142) Assay may be associated with enhanced patient benefit with the therapies listed in Table 2 for the corresponding indication and cutoffs in accordance with the approved therapeutic product labeling.